Merck Sharp & Dohme disclosed new benzimidazole derivatives that act as NLRP3 inflammasome inhibitors through a patent filing. The company framed potential use across indications spanning atherosclerosis, MASH, neuroinflammation, inflammatory skin and joints, autoimmune diseases, and neurodegenerative disorders such as Alzheimer’s and Parkinson’s. The disclosure continues the race to validate NLRP3 as a disease-modifying target, where next questions typically center on potency, selectivity, and durability of inflammasome suppression.